Glioblastoma Multiforme Therapeutics in Major Developed Markets to 2019 - Growth to Hinge on the Success of Personalized Vaccine Following Early Approval in Germany

During the 2012-2019 forecast period, the GBM market is expected to grow rapidly from $305m to $583m. The market entry of Northwest Biotherapeutics’ DCVax-L, a dendritic cell-based therapeutic vaccine that acts as an add-on to the standard treatment in newly diagnosed patients, will account for much of this growth.